ADC Therapeutics (NYSE:ADCT) has submitted marketing application with FDA seeking approval for loncastuximab tesirine (Lonca) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
The company says that the application is based on efficacy and safety data from LOTIS 2 clinical trial. In June, the company announced interim data from LOTIS 2 study, demonstrating encouraging action.
Lonca (formerly ADCT-402) is an antibody drug conjugate composed of a humanized monoclonal antibody directed against human CD19.
Lonca is being evaluated in pivotal LOTIS 2 (Phase 2) trial in patients with relapsed or refractory DLBCL, LOTIS 3, a Phase 1/2 trial in combination with ibrutinib in patients with relapsed or refractory DLBCL or mantle cell lymphoma.
The company has also commenced LOTIS 5 (Phase 3) confirmatory trial of Lonca in combination with rituximab, which is intended to support a supplemental marketing application for Lonca to be used as a second-line therapy for the treatment of relapsed or refractory DLBCL.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.